Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases.
We analyzed data from 18 898 adults (age ≥20 years) and 2836 children/adolescents reported in the Surveillance, Epidemiology and End Results (SEER) database as having Hodgkin lymphoma (HL), diagnosed from 1988 to 2005. The nodular sclerosis subtype was significantly more common in the pediatric age group (76% in children/adolescents vs. 61% in adults, p < 0.001). The mixed cellularity subtype was more prevalent in children <10 years old (22%), but less likely in older children/adolescents (8.5%). Systemic symptoms were reported in 39% of children/adolescents and in 48% of adults (p < 0.001). Children/adolescents had significantly better HL-specific survival than adults (5-year survival rate, 96% ± 0.4% vs.88% ± 0.3%, p < 0.001). Using a Cox proportional-hazards regression model in patients with classical HL, the prognostic factors significantly impacting survival were age, histology, stage, B symptoms, year of diagnosis, and race. The only adverse prognostic factors that were significant when this analysis was restricted to children/adolescents were stage IV disease and the presence of B symptoms. In conclusion, several differences in clinicopathologic features and outcomes were identified between children/adolescents and adults with HL, and this was particularly noted in young children (<10 years).
Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan.
Faiha
F
Bazzeh
Rawad
R
Rihani
Scott
S
Howard
Iyad
I
Sultan
D000293:Adolescent; D000328:Adult; D002423:Cause of Death; D002648:Child; D023381:Endpoint Determination / Q000379:methods* / Q000706:statistics & numerical data; D005260:Female; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D011159:Population Surveillance / Q000379:methods; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult